Cellectar Biosciences shares are trading lower. The company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.
Portfolio Pulse from Benzinga Newsdesk
Cellectar Biosciences shares are trading lower following the announcement of results from its CLOVER WaM pivotal study evaluating iopofosine I 131.
July 23, 2024 | 11:48 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Cellectar Biosciences shares are trading lower after the company announced results from its CLOVER WaM pivotal study evaluating iopofosine I 131.
The announcement of study results has led to a negative market reaction, causing the stock to trade lower. This suggests that the results may not have met investor expectations.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100